WO2009134010A2 - Composition pharmaceutique aux extraits d'herbes destinée à la prévention et au traitement de l'obésité et des troubles métaboliques - Google Patents

Composition pharmaceutique aux extraits d'herbes destinée à la prévention et au traitement de l'obésité et des troubles métaboliques Download PDF

Info

Publication number
WO2009134010A2
WO2009134010A2 PCT/KR2009/001542 KR2009001542W WO2009134010A2 WO 2009134010 A2 WO2009134010 A2 WO 2009134010A2 KR 2009001542 W KR2009001542 W KR 2009001542W WO 2009134010 A2 WO2009134010 A2 WO 2009134010A2
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
extract
weight
treatment
composition
Prior art date
Application number
PCT/KR2009/001542
Other languages
English (en)
Korean (ko)
Other versions
WO2009134010A3 (fr
Inventor
이경희
이용오
김유선
조영석
홍준기
Original Assignee
주식회사 유유
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 유유 filed Critical 주식회사 유유
Priority to CN2009801153374A priority Critical patent/CN102014944B/zh
Publication of WO2009134010A2 publication Critical patent/WO2009134010A2/fr
Publication of WO2009134010A3 publication Critical patent/WO2009134010A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/754—Evodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a composition for preventing or treating obesity and metabolic syndrome using a composite herbal medicine.
  • Obesity was already prescribed as a disease in 1996 by the World Health Organization. About 150 million people worldwide have experienced obesity, a health risk factor, and since obesity is directly related to various adult diseases, there is an urgent need for treatment for obesity. In addition, the market size of obesity drugs is on the rise due to the improvement of economic level and increased interest in appearance.
  • Obesity is a problem that obesity itself causes constipation, indigestion, gastrointestinal disorders due to the abdominal pressure by the fat tissue, as well as the risk factors of many adult diseases. Obesity is known to cause all kinds of complications such as cancer, arteriosclerosis, heart disease, high blood pressure, diabetes and other complications, and in 1996, the World Health Organization (WHO) warned that obesity is a disease that needs treatment.
  • WHO World Health Organization
  • Metabolic syndrome is characterized by insulin resistance, abdominal obesity, hyperlipidemia, hypertension, hyperglycemia, and is a particularly frequent symptom in obese people.
  • the WHO warned the American Medical Association (JAMA) that anyone with a metabolic syndrome is more likely to become a diabetic, stroke or heart disease patient.
  • JAMA American Medical Association
  • Metabolic syndrome patients are those who overlap three or more of the following five symptoms.
  • Obesity is a condition where excess fat is accumulated in the body, and fat is accumulated in the body due to excessive intake of sugar (carbohydrate) or excessive intake of fat.
  • sugar carbohydrate
  • the mechanism of reaching obesity is that by over-ingesting the sugar, the sugar in the food is digested and becomes monosaccharide and absorbed into the body through the small intestine.Increased blood sugar increases insulin secreted by the stimulus and acts on fat cells to release the monosaccharide in the blood. Fat cells are taken in and converted into fat.
  • fat which is the highest calorie among food ingredients, is broken down by pancreatic lipase and absorbed through the small intestine, resulting in an increase in stored calories due to excess calories. That is, obesity is caused by excess fat intake.
  • Glycolytic digestion which inhibits the path to obesity due to excessive intake of glucose, suppressed the rise in blood sugar, or suppressed the adsorption of cholic acid, which inhibits the path to obesity, by inhibiting the absorption of monosaccharides or by excessive intake of fat, cholesterol lowering It is thought that obesity can be prevented and improved by the action, the blood triglyceride lowering action, or the lipase inhibitory action, and the research on the pharmaceutical component which has these actions is continuing.
  • Glycolytic digestive enzyme inhibitors currently being used as drugs include acarbose (Acarbose, Bayer Pharmaceutical Co., Ltd.) and Bogriboose (AO-128, Daeda Pharmaceutical Co., Ltd.), a post-prandial hyperglycemic improver. These animals have been shown to have an inhibitory effect on post-prandial blood sugar levels in animal and clinical trials. Exp. Med.vol. 175, 87 (1979), Japanese Society for Agricultural Chemistry vol. 63, 217 (1989), New Current vol. 6, 2 (1995).
  • methods of inhibiting the path leading to obesity by ingesting fat include cholic acid adsorption excretion, cholesterol lowering, blood triglyceride lowering, lipase inhibition, and the like.
  • Drugs with cholic acid excretion include cholstyramine, a hypercholesterolemic drug, which is an anion exchange resin.
  • the anion exchange resin is circulated in the gut [Makino Isaora, Taisha, vol. 24, No.
  • adsorption and fixation of the intestinal cholic acid prevents resorption of the cholic acid, promotes the conversion of cholesterol into the cholic acid in the liver, and consequently lowers the blood cholesterol concentration.
  • the usage of cholestyramine is that 9 g is taken in 100 mL of water, so the dose is very high, and when taken, the rough unpleasant texture of the resin remains in the mouth, making it very difficult for the patient to take it. There was a problem.
  • Some anti-obesity drugs have been developed, which consist of extracts of several herbal drugs or mixtures.
  • Korean Patent Publication No. 2007-0042755 discloses a composition for inhibiting or treating obesity using a ginseng component, and in KR0733336, a composition for preventing or treating obesity or hyperlipidemia using a root is registered.
  • the applicant of the patent has registered a patent for the treatment of obesity using the herbal medicines such as white hair roots and the inhibitory composition (or extract) through the registration publications KR0573590, KR0573591 and KR0573592, but further research has been found to be superior in abdominal fat reduction. It is a new invention of the composition of the present invention to effect.
  • the present inventors confirmed that the complex extracts of the herbal medicines, Osuyu, Baek-geun-geun and Cheongpi, were effective in inhibiting weight gain, abdominal fat reduction, and triglyceride and blood glucose levels through animal experiments.
  • in vitro tests confirmed the effect of increasing the activity of AMPK enzyme, a biomarker associated with obesity and diabetes, and also confirmed the effect of increasing glucose uptake in myocytes and adipocytes.
  • an object of the present invention is to provide a composition for the prevention and treatment of obesity and metabolic syndrome, which contains a complex extract of Evodiamine Fructus , Cerrus Unshiu Markovich and White Hair Root (Imperatae Rhizoma) as an active ingredient.
  • the present invention has another object to provide a health food containing the complex extract.
  • An object of the present invention is to provide a composition for the prevention and treatment of obesity and metabolic syndrome, which contains a complex extract of Evodiamine Fructus , Cerrus Unshiu Markovich and White Root Muscle (Imperatae Rhizoma) as an active ingredient.
  • the complex extract includes a health food containing the complex extract.
  • the complex extract according to the present invention promotes the expression of genes related to the prevention and treatment of obesity and metabolic syndrome in cells, and has a very good weight gain inhibitory effect and high levels of triglycerides and blood glucose in blood in mice fed high fat diet. Improves glucose uptake in myocytes and adipocytes.
  • Figure 1 shows the combined effect of the present invention AMPK enzyme activity using the obese animal model.
  • Figure 3 is a measure of the increase in glucose uptake capacity in the muscle cells of the complex extract according to the present invention.
  • Figure 4 measures the increase in glucose uptake capacity in mast cells of the complex extract according to the present invention.
  • the present invention for achieving the above object, in the composition for the prevention and treatment of obesity and metabolic syndrome containing a complex extract of sorghum ( Evodiamine Fructus ), cheongpi (Citrus Unshiu Markovich) and white hair root (Imperatae Rhizoma) as an active ingredient It is about.
  • sorghum Evodiamine Fructus
  • cheongpi Citrus Unshiu Markovich
  • white hair root Imperatae Rhizoma
  • the complex extract according to the present invention may be prepared by first obtaining a method such as cold water extraction, hot water extraction or solvent extraction according to a conventional method, drying, and then mixing in the above ratio.
  • each herbal may be extracted in different ways. For example, it can be manufactured by the following method.
  • each of the sewage, skin and white hair roots that have been screened and cut to the appropriate size are prepared.
  • 0.1 to 10 parts by weight of cheongpi, 0.1 to 30 parts by weight of white hair root are used based on 1 part by weight of sewage oil.
  • 10 to 100 times the amount of each aqueous solution of alcohol is added, extraction is performed for 4 to 8 hours at 70 to 100 ° C., followed by rapid freezing for 10 to 20 hours at -50 to -30 ° C., and 30 to 30 at a pressure of 0.1 to 0.5 Torr.
  • the dry powder of each herbal medicine is mixed by the said ratio, and the composite extract powder which concerns on this invention is obtained.
  • the solid content of each herbal extract before drying may be investigated in advance, and then the extract may be mixed so as to have the above ratio, and then dried in a batch to obtain a composite extract powder according to the present invention.
  • the composite extract according to the present invention may be obtained by first mixing each herbal dry matter of a calculated ratio so as to finally be the above ratio, and then extracting them in a batch.
  • a mixture of 1.0 parts by weight of dried sewage extract, 0.1 to 10 parts by weight of dried skin extract and 0.1 to 30 parts by weight of dried white hair root extract is prepared by a method such as cold water extraction, hot water extraction or solvent extraction according to a conventional method.
  • the mixture may be used as it is by filtration, concentrated to use, or lyophilized to be used as powder.
  • it can be manufactured by the following method. First, the sewage, skin and white hair roots, which have been selected and trimmed to an appropriate size, are mixed in accordance with the mixing ratio.
  • the complex extract according to the present invention can be seen in the preparation examples and examples below, by increasing the cellular uptake of AMPK at the same time to increase the intracellular AMPK activity, a conventional conventional herbal medicine or commercial drugs for the treatment and inhibition of obesity It is much better and safer than that.
  • the complex extract of the present invention can be prepared as a pharmaceutical.
  • the complex extract of the present invention can be administered to mammals such as mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
  • the present invention provides a health functional food comprising the composition and a food acceptable food supplement additive exhibiting a prophylactic and therapeutic effect of obesity and metabolic syndrome.
  • a food acceptable food supplement additive exhibiting a prophylactic and therapeutic effect of obesity and metabolic syndrome.
  • the food to which the complex extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
  • the present invention includes a health food for improving obesity and metabolic syndrome containing a complex extract as an active ingredient.
  • the health food may contain various supplemental herbal medicines, vitamins, minerals, dietary fiber, and other medicinal-food supplements (eg, excipients, enhancers, coatings, etc.).
  • the amount of the complex extract in the food or beverage in the case of the health food of the present invention can generally be added to 0.0001 to 100% by weight, preferably 80% by weight or less of the total food weight, 100 ml to the health beverage composition It can be added in a ratio of 0.0001 to 10 g, preferably 5.0 g or less as a reference.
  • a 10-fold weight of 70% aqueous ethanol solution was mixed with 1 Kg of dried sewage, white hair root and skin skin, which were previously screened and cut into appropriate sizes, and then heated and subjected to primary extraction at 85 ° C. for 6 hours. Thereafter, the primary filtrate was collected separately by filtration, and the filtered crude drug was further mixed with an aqueous 10% weight 70% ethanol aqueous solution, followed by heating to carry out secondary extraction at 85 ° C. for 6 hours. Subsequently, the resultant was filtered to obtain a secondary filtrate, followed by rapid freezing with the primary filtrate at 70 ° C. for 12 hours, vacuum drying for at least 36 hours under a pressure of 0.23 Torr or less, and then grinding to obtain respective dry powders.
  • the obtained sewage oil, white hair root and dermis extract powder was mixed with 1 part by weight of white hair root extract and 3 parts by weight of dermis extract based on 1 part by weight of sewage extract to obtain a composite extract powder (composite extract) of the present invention.
  • each dry herbal medicine was mixed in the final extract. That is, dry sewage oil, white hair root and green skin, which were previously screened and cut to an appropriate size, were mixed, a 10-fold weight of 70% ethanol aqueous solution was poured, and heated to carry out primary extraction at 85 ° C. for 6 hours. Thereafter, the primary filtrate was collected separately by filtration, and the filtered crude drug was further mixed with an aqueous 10% weight 70% ethanol aqueous solution, followed by heating to carry out secondary extraction at 85 ° C. for 6 hours. Subsequently, the resultant was filtered to obtain a secondary filtrate, followed by rapid freezing with the primary filtrate at 70 ° C. for 12 hours, vacuum drying for at least 36 hours under a pressure of 0.23 Torr or less, and then grinding to obtain respective dry powders.
  • the cells were treated with the composite extract of the preparation, and then AMPK activity was examined over time. Activation of the AMPK enzyme increases glucose uptake, inhibits fatty acid synthesis, and induces fatty acid oxidation, and thus this experiment can confirm the prophylaxis or treatment of obesity and metabolic syndrome of the complex extract of the present invention.
  • mice purchased 20 to 25 g of 6-week-old C57BL / 6 mice from the central laboratory animals, and allowed them to freely feed and water in the animal room, and after one week, divided them into four groups as follows.
  • HFD High Fat Diet
  • mice were separated by weight, and 5 mice were placed in cages so that an average of 36 to 37 g of HFD was put into two cages (10 mice).
  • the average diet weight was 27 g.
  • High-fat diet mice were orally administered with the complex extract of the present invention for 10 weeks every day to observe the weight change and intake of the mice.
  • HFD normal diet control diet fed a normal diet
  • HFD high fat diet control group fed 45% high fat diet
  • HFD + complex extract high fat diet + complex extract (500 mg / kg)
  • HFD + sibutramine high fat diet Used as a positive control with this + sibutramine (2 mg / kg).
  • blood was collected from the orbital vein, and each tissue was extracted and weighed for analysis.
  • blood index analysis blood collection was performed using plasma after centrifugation of whole blood obtained from the orbital vein for 30 minutes at 1,500 rpm after fasting on the previous day (8-10 hours), and astaxet triglycerides, glucose and cholesterol. (cholesterol) kits were purchased and measured with an ELISA reader.
  • Figure 2 is the result of comparing the weight change pattern between each group for 10 weeks.
  • the body weight of the mice was temporarily decreased until 2 weeks. This may be due to the stress of the mouse by oral administration.
  • Body weight gained again from 3 weeks, and significantly increased weight suppression effect in group administered 500 mg / kg of complex extract at 5 weeks compared with control group. This effect lasted up to 10 weeks.
  • the body weight of the high-fat diet group HFD
  • the complex extract group was 41.3 at the 500 mg / kg dose, respectively. ⁇ 1.7.
  • the weight of the sibutramine-treated group which was a positive control group, was 43.3 ⁇ 1.7, which was lower than that of the high-fat diet.
  • the complex extract of the present invention was found to have better activity in weight inhibition than the positive control group.
  • the high fat diet significantly increased abdominal fat, significantly increased liver and kidney weights, and the weight of other organs was not significantly changed.
  • the high-fat diet group was 4.5 ⁇ 0.5, whereas the combined extracts showed 3.2 ⁇ 0.4 of abdominal fat reduction on average by 30%.
  • Table 2 shows the plasma-derived plasma of the mice obtained from orbital vein after fasting overnight (8 hours) after oral administration of the complex extract to diet-induced obesity for 10 weeks. Blood glucose and cholesterol were analyzed.
  • the high-fat diet control group HFD
  • the complex extract group was 123.4 ⁇ 12.2 at 500 mg / kg dose compared to the high-fat diet control group. Neutral lipid reduction effect was shown.
  • the high-fat diet control group increased 255.6 ⁇ 30.1 mg / dL compared to the general diet group (RD), whereas the complex extract group showed 204.1 ⁇ 14.5 mg / dL at 500 mg / kg dose.
  • the blood glucose reduction effect was shown.
  • the high fat diet was more effective than the control group, but the cholesterol was less correlated with the body weight.
  • the composite extract according to the present invention was found to be useful for the reduction of neutral lipid and blood glucose levels as well as the weight loss effect.
  • the complex extract of the present invention was dissolved in water and treated with different concentrations of cells for 24 hours, followed by MTT analysis to select the highest cytotoxicity (cytotoxic) concentration and glucose absorption ability in C2C12 myocytes (Fig. 3).
  • the complex extract of the present invention was observed to increase glucose uptake better than insulin at a 100 ⁇ g / mL dose, which is considered to be effective for glucose uptake.
  • the composite extract of the present invention was dissolved in water to investigate the effect on glucose uptake using 3T3L1 adipocytes at low concentrations of cytotoxicity (FIG. 4).
  • the complex extract of the present invention was observed to increase glucose uptake to a similar extent to 100 nM insulin, indicating a good glucose uptake effect.
  • the composite extract according to the present invention confirmed the effect of inhibiting weight gain and improving neutral lipid and blood glucose levels through animal experiments and enhancing the activity of AMPK enzyme, a biomarker related to the prevention or treatment of obesity and metabolic syndrome, through in vitro tests. It was confirmed that the effect of increasing the glucose uptake capacity in myocytes and adipocytes.
  • the composite extract according to the present invention was confirmed that it can be usefully applied to the treatment and prevention of diseases associated with obesity and metabolic syndrome.
  • the above ingredients were mixed and prepared in a conventional manner, and then injected into a 2 ml ampoule and sterilized to prepare an injection.
  • the tablets were prepared by mixing the above components and tableting according to a conventional method for producing tablets.
  • the capsules were prepared by mixing the above components and filling the capsules according to a conventional method for preparing capsules.
  • Purified water was added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed to prepare a liquid.
  • Vitamin A (0.275 mg as Retinyl Palmitate) &........ 500 IU
  • Vitamin C ... ..50 mg
  • Glycerin ginseng calcium (4.76 mg as calcium) ... 25 mg
  • Iron sulphate (5.0 mg as iron) ... 15.45 mg
  • composition ratio of the complex extract of the present invention, vitamins and minerals, etc. are mixed with the components suitable for the health functional food in a preferred embodiment, the composition ratio may be arbitrarily modified, and according to the conventional health functional food manufacturing method After mixing the above components to prepare a granule, it can be used for preparing a nutraceutical composition according to a conventional method.
  • Purified water was added to adjust the total volume to 900 ml. It is prepared according to a conventional healthy beverage manufacturing method.
  • composition ratio is a composition that is relatively suitable for a preferred beverage in a preferred embodiment
  • the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition aux extraits d'herbes composites destinée à la prévention et au traitement de l'obésité et des troubles métaboliques. En particulier, l'invention porte sur une composition contenant de l'Evodiae Fructus, de l'Imperatae Rhizoma, et du Citrus unshiu Markovich, qui est destinée à prévenir et traiter l'obésité et le syndrome métabolique ou syndrome X.
PCT/KR2009/001542 2008-04-29 2009-03-26 Composition pharmaceutique aux extraits d'herbes destinée à la prévention et au traitement de l'obésité et des troubles métaboliques WO2009134010A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009801153374A CN102014944B (zh) 2008-04-29 2009-03-26 利用复合药材的肥胖及代谢综合征的预防或治疗用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0039874 2008-04-29
KR20080039874A KR101511364B1 (ko) 2008-04-29 2008-04-29 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물

Publications (2)

Publication Number Publication Date
WO2009134010A2 true WO2009134010A2 (fr) 2009-11-05
WO2009134010A3 WO2009134010A3 (fr) 2009-12-23

Family

ID=41255515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001542 WO2009134010A2 (fr) 2008-04-29 2009-03-26 Composition pharmaceutique aux extraits d'herbes destinée à la prévention et au traitement de l'obésité et des troubles métaboliques

Country Status (3)

Country Link
KR (1) KR101511364B1 (fr)
CN (1) CN102014944B (fr)
WO (1) WO2009134010A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014208799A1 (fr) * 2013-06-28 2014-12-31 재단법인 아산사회복지재단 Composition pour la prévention ou le traitement de la stéatose hépatique comprenant un extrait d'evodiae fructus et un composé alcaloïde isolé à partir de celui-ci comme ingrédients actifs
CN109288843A (zh) * 2018-11-19 2019-02-01 青岛大学 吴茱萸碱的降血脂作用
RU2727465C1 (ru) * 2019-07-15 2020-07-21 Игорь Фёдорович Душкин Способ восстановительного лечения больных с метаболическим синдромом на санаторно-курортном этапе
KR20240080809A (ko) 2022-11-30 2024-06-07 한국한의약진흥원 항비만 활성이 증가된 오수유의 생물전환 추출물 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047209A1 (fr) * 1996-06-12 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Amelioration du metabolisme lipidique
KR19990011833A (ko) * 1997-07-25 1999-02-18 김이현 부인과 질환 및 여성비만 치료용 약제 조성물과 이를 이용한 약제의 제조방법
KR20050078601A (ko) * 2004-02-02 2005-08-05 주식회사 유유 비만치료ㆍ억제용 생약 조성물
WO2005072757A1 (fr) * 2004-02-02 2005-08-11 Yuyu Inc. Extrait d'imperatae rhizoma utile dans le traitement et la prevention de l'obesite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224299A1 (en) * 2006-03-23 2007-09-27 Talbot Shawn M Weight loss with citrus flavonoids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047209A1 (fr) * 1996-06-12 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Amelioration du metabolisme lipidique
KR19990011833A (ko) * 1997-07-25 1999-02-18 김이현 부인과 질환 및 여성비만 치료용 약제 조성물과 이를 이용한 약제의 제조방법
KR20050078601A (ko) * 2004-02-02 2005-08-05 주식회사 유유 비만치료ㆍ억제용 생약 조성물
WO2005072757A1 (fr) * 2004-02-02 2005-08-11 Yuyu Inc. Extrait d'imperatae rhizoma utile dans le traitement et la prevention de l'obesite

Also Published As

Publication number Publication date
WO2009134010A3 (fr) 2009-12-23
CN102014944B (zh) 2012-10-03
KR101511364B1 (ko) 2015-04-10
CN102014944A (zh) 2011-04-13
KR20090114093A (ko) 2009-11-03

Similar Documents

Publication Publication Date Title
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
US7959956B2 (en) Method for treating diabetic complications
JP6145552B1 (ja) 脂肪肝治療用組成物
WO2009134010A2 (fr) Composition pharmaceutique aux extraits d'herbes destinée à la prévention et au traitement de l'obésité et des troubles métaboliques
WO2018093237A2 (fr) Composition comprenant de l'acide formique ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif pour la prévention ou le traitement de l'obésité ou des syndromes métaboliques provoqués par l'obésité
CN100345566C (zh) 一种用于减肥的药物组合物及其制备方法和用途
WO2016148545A1 (fr) Composition pour prévenir ou améliorer des symptômes d'andropause
KR20110105627A (ko) 누에 체액을 함유하는 항비만 조성물
WO2011019210A9 (fr) Supplément diététique, composition alimentaire et pharmaceutique contenant de la graine de chia et du maca, procédé de préparation correspondant
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
CN110624067B (zh) 具有减肥作用的中药组合物及其药膏的制备方法
KR20150012926A (ko) 구절초 추출물을 포함하는 항비만 조성물
WO2017082501A1 (fr) Composition visant à prévenir ou traiter les troubles de la ménopause et contenant de l'extrait de tetragonia tetragonoides (pall.) kuntze
KR20140114950A (ko) 백두구 추출물을 포함하는 항비만 조성물
KR102192586B1 (ko) 아위버섯의 추출물 또는 분말을 유효성분으로 함유하는 지방간 질환 치료용 약학적 조성물 및 간기능 개선용 건강기능식품
CN105995971A (zh) 一种促进糖尿病康复的营养流食及其制备方法
WO2021246703A1 (fr) Composition anti-obésité
KR20190111726A (ko) 천연 혼합 추출물을 포함하는 비만 예방 또는 치료용 조성물
KR20210085665A (ko) 차전자를 함유하는 건강증진용 조성물
KR100573592B1 (ko) 비만치료·억제용 백모근 추출물
WO2020159038A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'obésité, contenant un extrait d'aloe vera, de pseudocydonia sinensis et de zea mays linne en tant que principe actif
CN114796417B (zh) 一种降血糖中药组方及其制备方法
WO2023204364A1 (fr) Composition permettant la prévention, l'amélioration ou le traitement de maladies respiratoires allergiques comprenant un extrait d'alpinia officinarum hance en tant que principe actif
KR100773246B1 (ko) 연령초 추출물을 유효성분으로 함유하는 비만 억제 및 혈당강하용 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980115337.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09738917

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09738917

Country of ref document: EP

Kind code of ref document: A2